IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Cisplatin is a widely used chemotherapeutic agent for the treatment of various malignant neoplasms, including testicular, ovarian, bladder, cervix uteri, head and neck and lung cancers.
One of the common side-effects of this drug is bilateral, symmetric, progressive and usually irreversible sensorineural hearing loss.
Cisplatin induces cochlear toxicity by the production of reactive oxygen species (ROS).
Dexamethasone treatment is currently practiced for various pathologies afflicting the inner ear. The positive effect of Dexamethasone is attributed to it's anti ROS activity and it's capability to up-regulate cochlear anti ROS enzymes.
In order to reach higher inner ear concentration of the drug while avoiding it's undesirable systemic side-effects, Intratympanic (IT) delivery of Dexamethasone became vastly used in the last decades for the treatment of sudden sensorineural hearing loss and Meniere's disease.
Dexamethasone inserted IT, diffuse across the round window into the inner ear perilymph where it exerts its therapeutic effects.
The investigators review of the literature yielded three animal studies which examined the protective effect of IT dexamethasone in the prevention of cisplatin-induced hearing loss. These studies demonstrated promising results pointing to the potential for IT dexamethasone in the prevention of cisplatin ototoxicity in humans.
The purpose of this study is to examine possible protective effect of IT dexamethasone on cisplatin-induced hearing loss, in humans.
The study hypothesis is that IT dexamethasone treatment would prevent cisplatin-induced hearing loss.
| Condition | Intervention | Phase |
|---|---|---|
| Cisplatin Ototoxicity | Drug: Dexamethasone Phosphate | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention |
| Official Title: | Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment. |
- Examine possible protective effect of IT dexamethasone on cisplatin-induced hearing loss. Hearing assessment would include:pure tone, speech and impedance audiometry, and Distortion Product Otoacoustic Emissions (DPOAEs) testing. [ Time Frame: Two years ]Distortion Product Otoacoustic Emissions (DPOAEs) testing is a test that specifically evaluates the functioning of the cochlear outer hair cells which are the primary target organ for cisplatin ototoxicity.
| Enrollment: | 30 |
| Study Start Date: | June 2011 |
| Study Completion Date: | June 2013 |
| Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Dexamethasone |
Drug: Dexamethasone Phosphate
0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle. The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level. Other Name: Decadron, Dexamethasone Intensol, Dexpak Taperpak, Zema Pak
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients suffering from a neoplastic disease for which the treatment protocol includes cisplatinum not previously delivered to them.
- The cumulative cisplatin dose would be at least 300mg.
Exclusion Criteria:
- Age < 18 years.
- Existing or previous pathology of the external or middle ear avoiding IT drug delivery or the performance of DPOAEs testing.
- Retrocochlear hearing loss.
- Meniere's disease.
- Autoimmune Inner Ear Disease.
- fluctuating hearing loss.
- History of sudden sensory neural hearing loss.
- Previous radiation therapy to the head and neck region.
- Baseline average pure tone audiometry thresholds for 500-3000 Hz and 4000-8000 Hz greater than 40 dB.
- Average SNR below 6 dB for DPOAEs f2 frequencies 500-3000 Hz and 4000-8000 Hz.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01372904
| Israel | |
| Clalit Health Services | |
| Haifa, Israel | |
| Principal Investigator: | Tal M Marshak, MD | Clalit Health Services |
More Information
| Responsible Party: | Meir Medical Center |
| ClinicalTrials.gov Identifier: | NCT01372904 History of Changes |
| Other Study ID Numbers: |
CIS 4/2011 |
| Study First Received: | June 13, 2011 |
| Last Updated: | July 16, 2014 |
Keywords provided by Meir Medical Center:
|
Cisplatin Hearing loss Ototoxicity Intratympanic injection |
Dexamethasone Steroids Prevention |
Additional relevant MeSH terms:
|
Hearing Loss Deafness Hearing Disorders Ear Diseases Otorhinolaryngologic Diseases Sensation Disorders Neurologic Manifestations Nervous System Diseases Signs and Symptoms Cisplatin Dexamethasone Dexamethasone acetate Dexamethasone 21-phosphate BB 1101 |
Antineoplastic Agents Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on August 21, 2017